Rubery Paul T, Bukata Susan V
Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, NY 14642, USA.
J Spinal Disord Tech. 2010 Apr;23(2):151-5. doi: 10.1097/BSD.0b013e31819a8b7a.
Case Report.
To report on the treatment of 3 cases of painful delayed unions of type III odontoid fractures with teriparatide.
Fractures of the C2 vertebra, also known as odontoid fractures, are an important subset of cervical spine fractures. Type III odontoid fractures pass through predominately cancellous bone of C2. Generally accepted treatment is external immobilization with either a rigid collar or a halo vest for 8 to 12 weeks. We report 3 patients who, despite external immobilization, developed painful delayed unions of type III odontoid fractures. Teriparatide is a novel anabolic drug therapy for osteoporosis. It has been shown to stimulate osteoblasts, enhance bone connectivity, increase endosteal cortical thickness, and improve bone mineral content. The drug is given through subcutaneous injection of 20 microg/d for between 6 weeks and 2 years. We treated these 3 patients with teriparatide. Each was informed that details of their case would be submitted for publication.
Retrospective case analysis.
All 3 patients experienced both rapid clinical improvement and computed tomography evidence of fracture union.
These 3 cases represent relatively uncommon clinical scenarios in which type III odontoid fractures in osteoporotic women failed to unite with external immobilization over several months. The patients presented for follow-up with substantial, activity-limiting neck pain. All 3 were begun on teriparatide doses therapeutic for osteoporosis, and all 3 experienced both remarkable resolution of chronic neck pain and computed tomography-confirmed union of the fractures.
病例报告。
报告3例Ⅲ型齿状突骨折疼痛性骨不连患者使用特立帕肽的治疗情况。
C2椎体骨折,又称齿状突骨折,是颈椎骨折的一个重要亚型。Ⅲ型齿状突骨折主要穿过C2的松质骨。一般公认的治疗方法是使用硬领或头环背心进行外部固定8至12周。我们报告3例患者,尽管进行了外部固定,但仍发生了Ⅲ型齿状突骨折疼痛性骨不连。特立帕肽是一种用于治疗骨质疏松症的新型促合成代谢药物疗法。已证明它能刺激成骨细胞,增强骨连接性,增加骨内膜皮质厚度,并改善骨矿物质含量。该药物通过皮下注射20微克/天,持续6周至2年。我们用特立帕肽治疗了这3例患者。每位患者均被告知其病例细节将提交发表。
回顾性病例分析。
所有3例患者均临床快速改善,且计算机断层扫描显示骨折愈合。
这3例代表了相对不常见的临床情况,即骨质疏松女性的Ⅲ型齿状突骨折经数月外部固定仍未愈合。患者因严重的、限制活动的颈部疼痛前来随访。所有3例患者均开始使用治疗骨质疏松症的特立帕肽剂量,且所有3例患者的慢性颈部疼痛均显著缓解,计算机断层扫描证实骨折愈合。